Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University, Ain Helwan, Helwan, Cairo 11795, Egypt.
National Tropical Medicine and Hepatology Research Institute, Cairo, Egypt.
Mediators Inflamm. 2019 Jan 9;2019:3273645. doi: 10.1155/2019/3273645. eCollection 2019.
Chronic inflammation is a pivotal contributor to the liver damage mediated by hepatitis C virus (HCV). The NOD-like receptor, pyrin domain-containing 3 (NLRP3) inflammasome is activated by HCV in both hepatocytes and Kupffer cells. The aim of our study was to investigate the association of nine single-nucleotide polymorphisms in four inflammasome genes (NLRP3, CARD8, IL-1, and IL-18) with the susceptibility to HCV infection and outcome of interferon treatment in 201 Egyptian chronic hepatitis C patients and 95 healthy controls. The genotyping was conducted using TaqMan predesigned SNP assay. In the comparative analysis, the CC genotype of the NLRP3 rs1539019 was found to be associated with the lower risk to chronic HCV infection (OR: 0.33, 95% CI: 0.17-0.62). This association was also found for the CA genotype and the A allele of the NLRP3 rs35829419 (OR: 0.18 and 0.22, respectively), in addition to the GG genotype and G allele of IL-18 rs1946518 (OR: 0.55 and 0.61, respectively). In contrast, the AA genotype of the IL-1 rs1143629 was significantly more frequent in HCV patients (OR: 1.7, 95% CI: 1-2.86). Notably, the frequency of the AA genotype of NLRP3 rs1539019 was significantly higher in patients with lack of response (NR) to the interferon treatment (OR: 1.95, 95% CI: 1-3.7). A similar association was found for both the CC genotype and C allele of the NLRP3 rs35829419 (OR: 2.78 and 2.73, respectively) and for the TT genotype and T allele of CARD8 rs2043211 (OR: 2.64 and 1.54, respectively). Yet, the IL-1 (rs1143629, rs1143634) and IL-18 (rs187238, rs1946518) polymorphisms did not show any significant association with response to interferon treatment. In conclusion, this study reports, for the first time, the association of genetic variations in NLRP3 with hepatitis C susceptibility and response to treatment in Egyptian patients. However, further large-scale studies are recommended to confirm our findings.
慢性炎症是丙型肝炎病毒(HCV)介导的肝损伤的关键因素。NOD 样受体,富含吡咯烷结构域 3(NLRP3)炎性小体在肝细胞和枯否细胞中被 HCV 激活。我们的研究目的是调查四个炎性小体基因(NLRP3、CARD8、IL-1 和 IL-18)中的九个单核苷酸多态性与埃及 201 例慢性丙型肝炎患者 HCV 感染易感性和干扰素治疗结局的相关性,并与 95 名健康对照进行比较。采用 TaqMan 设计的 SNP 检测方法进行基因分型。在比较分析中,发现 NLRP3 rs1539019 的 CC 基因型与慢性 HCV 感染的风险降低相关(OR:0.33,95%CI:0.17-0.62)。还发现 NLRP3 rs35829419 的 CA 基因型和 A 等位基因(OR:0.18 和 0.22)以及 IL-18 rs1946518 的 GG 基因型和 G 等位基因(OR:0.55 和 0.61)也与该结果相关。相反,IL-1 rs1143629 的 AA 基因型在 HCV 患者中更为常见(OR:1.7,95%CI:1-2.86)。值得注意的是,NLRP3 rs1539019 的 AA 基因型在无干扰素治疗反应(NR)的患者中频率明显更高(OR:1.95,95%CI:1-3.7)。NLRP3 rs35829419 的 CC 基因型和 C 等位基因(OR:2.78 和 2.73)以及 CARD8 rs2043211 的 TT 基因型和 T 等位基因(OR:2.64 和 1.54)也存在类似的关联。然而,IL-1(rs1143629、rs1143634)和 IL-18(rs187238、rs1946518)多态性与干扰素治疗反应无明显相关性。总之,本研究首次报道了 NLRP3 基因的遗传变异与埃及患者 HCV 易感性和治疗反应的相关性。然而,建议进行更大规模的研究来证实我们的发现。